ARTV Reports 71% ACR50 Response in Refractory RA Patients, FDA Alignment on Phase 3 Trial, Presents AlloNK Data at EULAR 2026
Artiva Biotherapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.46
-21% in 7d after detection
Post-detection moves
1h
—
1d
-2.7%
3d
-3.6%
7d
-21%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS